Evidence‑Based Pharmacologic Management of Asthma

Chronic Asthma Management

Inhaled corticosteroids (ICS) are the most consistently effective long‑term control medication for persistent asthma and should form the therapeutic foundation for all patients with persistent disease. 1
For intermittent asthma (Step 1), a short‑acting beta‑agonist (SABA) is used only as needed. 2
When SABA use exceeds 2 days per week (excluding use for exercise prophylaxis), therapy should be escalated to Step 2. 1
In mild persistent asthma (Step 2), leukotriene receptor antagonists are an acceptable alternative to low‑dose ICS but are not the preferred controller therapy. 1
As‑needed SABA remains appropriate for symptom relief in mild persistent asthma. 2
In moderate persistent asthma (Step 3), long‑acting beta‑agonists (LABA) must never be prescribed as monotherapy because they increase exacerbations and mortality when used without an anti‑inflammatory agent. 1
For Step 3, increasing the ICS dose to a medium level is considered equally appropriate to adding a LABA to low‑dose ICS. 1
In severe persistent asthma (Step 4‑5), omalizumab should be considered for patients with severe allergic asthma that remains uncontrolled on high‑dose ICS + LABA. 3
Indicators that asthma control is inadequate and that step‑up therapy is needed include: SABA use > 2 days/week, SABA use > 2 nights/month, nocturnal awakenings, activity limitation, and peak expiratory flow < 80 % of predicted or personal best. 1

Patients should initiate a written asthma action plan at home when symptoms worsen progressively, peak flow falls below 60 % of personal best, sleep is disturbed by asthma, or morning symptoms persist until midday. 2, 4
Immediate home treatment consists of increasing SABA frequency (repetitive or continuous administration) and starting oral systemic corticosteroids without delay. 2

Adults: Prednisone 40–60 mg daily (or prednisolone 30–60 mg) is given until peak flow reaches ≥ 70 % of predicted or personal best; typical course is 5–10 days (up to 21 days if needed). No taper is required for courses ≤ 2 weeks. 5
Children: 1–2 mg/kg/day (maximum 60 mg/day) for 3–10 days; short courses do not require tapering. 5

Severe exacerbation is defined by inability to speak full sentences, respiratory rate > 25 /min (adults) or > 50 /min (children), heart rate > 110 /min (adults) or > 140 /min (children), and peak flow < 50 % predicted. 2, 5
Objective lung‑function measurements (spirometry or peak flow) are more reliable than symptoms alone for assessing severity. 2
Recommended treatment sequence:
Oral corticosteroids are equally effective as intravenous administration; the intravenous route offers no advantage. 5

Overreliance on bronchodilators without adequate anti‑inflammatory therapy worsens outcomes. 4
Delaying oral corticosteroids in moderate‑to‑severe exacerbations is associated with poorer outcomes. 1
Failure to provide a written asthma action plan increases risk of uncontrolled exacerbations. 2

History of a severe exacerbation requiring intubation or intensive‑care admission.
Two or more hospitalizations or more than three emergency‑department visits for asthma in the past year.
Use of more than two SABA canisters per month.
Difficulty perceiving the severity of airway obstruction.

Immunosuppressive agents (e.g., cyclosporine, methotrexate) and complementary approaches such as ionizers, acupuncture, and homeopathy have shown disappointing results in controlled trials and have no established role in routine asthma management. 4

The American Thoracic Society recommends that adults and adolescents with asthma receive ICS-containing therapy, either as regular maintenance or as-needed ICS-formoterol, to reduce severe exacerbations by ≥60% compared to SABA alone 7
The Global Initiative for Asthma (GINA) suggests verifying inhaler technique, medication adherence, and environmental trigger exposure before stepping up therapy 8, 9
Step down therapy should only be considered after 3 months of well-controlled asthma 10, 7

The American College of Allergy, Asthma, and Immunology recommends early treatment at home using a written asthma action plan, including increased SABA frequency and oral corticosteroids for severe episodes 11
The American Thoracic Society suggests monitoring peak flow, if available, particularly for patients with difficulty perceiving symptoms or a history of severe exacerbations 11
Objective lung function measures, such as spirometry or PEF, are more reliable than symptoms alone for classifying exacerbation severity 11
Severe exacerbation is defined as <40% predicted FEV1 or PEF, and discharge goal is ≥70% predicted FEV1 or PEF 8

The American Academy of Allergy, Asthma, and Immunology recommends multifaceted environmental control approaches, including identifying sensitizations, tobacco smoke avoidance, and HVAC maintenance 8, 12, 13
Allergen immunotherapy may be considered for patients with a clear relationship between symptoms and allergen exposure at Steps 2-4 10, 12

The National Asthma Education and Prevention Program recommends that all patients receive a written asthma action plan, including daily management instructions, recognition of worsening symptoms, and medication adjustment instructions 7, 9
Education should occur at all points of care, including clinics, emergency departments, hospitals, pharmacies, schools, community settings, and patients' homes 8, 9

The American College of Allergy, Asthma, and Immunology suggests scheduling follow-up visits based on control status, with more frequent visits for patients gaining control or stepping down therapy 12, 10
At every visit, assess days per week with symptoms, nighttime awakening, activity limitations, number of reliever medication puffs used daily, and spirometry at least every 1-2 years 12, 7